Li Ming, Yin Shiyao, Xu Anan, Kang Liyuan, Ma Ziqian, Liu Fan, Yang Tao, Sun Peng, Tang Yongan
Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Department of Otolaryngology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Pharmaceutics. 2023 Dec 26;16(1):33. doi: 10.3390/pharmaceutics16010033.
Oral squamous cell carcinoma (OSCC) contributes to more than 90% of all oral malignancies, yet the performance of traditional treatments is impeded by limited therapeutic effects and substantial side effects. In this work, we report a combinational treatment strategy based on tumor exosome-based nanoparticles co-formulating a photosensitizer (Indocyanine green) and a tyrosine kinase inhibitor (Gefitinib) (IG@EXOs) for boosting antitumor efficiency against OSCC through synergistic phototherapy-molecular targeted therapy. The IG@EXOs generate distinct photothermal/photodynamic effects through enhanced photothermal conversion efficiency and ROS generation, respectively. In vivo, the IG@EXOs efficiently accumulate in the tumor and penetrate deeply to the center of the tumor due to passive and homologous targeting. The phototherapy effects of IG@EXOs not only directly induce potent cancer cell damage but also promote the release and cytoplasmic translocation of Gefitinib for achieving significant inhibition of cell proliferation and tumor angiogenesis, eventually resulting in efficient tumor ablation and lymphatic metastasis inhibition through the synergistic phototherapy-molecular targeted therapy. We envision that the encouraging performances of IG@EXOs against cancer pave a new avenue for their future application in clinical OSCC treatment.
口腔鳞状细胞癌(OSCC)占所有口腔恶性肿瘤的90%以上,但传统治疗方法的疗效有限且副作用大,影响了其治疗效果。在本研究中,我们报告了一种基于肿瘤外泌体纳米颗粒的联合治疗策略,该纳米颗粒共负载一种光敏剂(吲哚菁绿)和一种酪氨酸激酶抑制剂(吉非替尼)(IG@EXOs),通过协同光疗-分子靶向治疗提高对OSCC的抗肿瘤效率。IG@EXOs分别通过提高光热转换效率和活性氧生成产生不同的光热/光动力效应。在体内,由于被动和同源靶向作用,IG@EXOs有效地在肿瘤中蓄积并深入渗透到肿瘤中心。IG@EXOs的光疗作用不仅直接诱导强大的癌细胞损伤,还促进吉非替尼的释放和细胞质转位,从而显著抑制细胞增殖和肿瘤血管生成,最终通过协同光疗-分子靶向治疗实现有效的肿瘤消融和淋巴转移抑制。我们设想,IG@EXOs在抗癌方面令人鼓舞的表现为其未来在临床OSCC治疗中的应用开辟了一条新途径。